Skip to main content
Erschienen in: Medical Oncology 12/2014

01.12.2014 | Original Paper

Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies

verfasst von: Daye Cheng, Ying Sun, Hu He

Erschienen in: Medical Oncology | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

In the past decade, several studies have suggested a possible link between circulating YKL-40 levels and endometrial carcinoma (EC), but have arrived at inconsistent results. Therefore, we conducted the present meta-analysis and aim to disclose a more comprehensive evaluation of the sensitivity, specificity, and diagnostic accuracy of YKL-40 in EC. We systematically searched PubMed, Embase, Web of Science, Science Direct, SpringerLink, EBSCO, Wanfang, and Chinese National Knowledge Infrastructure databases for studies that evaluated the diagnostic value of YKL-40 in endometrial cancer. The STATA software 12.0 and Meta-Disc software were used to test the heterogeneity and to evaluate the overall test performance. A total of seven studies including 234 EC cases and 300 controls were included in our meta-analysis. The summary estimates of YKL-40 for EC diagnosis indicated a moderately high diagnostic accuracy for circulating YKL-40, with a sensitivity of 0.74, a specificity of 0.87, a PLR of 5.74, a NLR of 0.30, a DOR of 19.14, and an AUC of 0.80. On the basis of our meta-analysis, therefore, circulating YKL-40 could be promising and meaningful in the diagnosis of EC.
Literatur
1.
2.
Zurück zum Zitat Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef Dobrzycka B, Mackowiak-Matejczyk B, Kinalski M, Terlikowski SJ. Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma. Gynecol Oncol. 2013;128:454–60.PubMedCrossRef
3.
Zurück zum Zitat Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef Wittenberger T, Sleigh S, Reisel D, et al. DNA methylation markers for early detection of women’s cancer: promise and challenges. Epigenomics. 2014;6:311–27.PubMedCrossRef
4.
Zurück zum Zitat Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef Renkema GH, Boot RG, Au FL, et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem. 1998;251:504–9.PubMedCrossRef
5.
Zurück zum Zitat Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef Fusetti F, Pijning T, Kalk KH, Bos E, Dijkstra BW. Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39. J Biol Chem. 2003;278:37753–60.PubMedCrossRef
6.
Zurück zum Zitat Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.PubMedCrossRef
7.
Zurück zum Zitat Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.PubMed
9.
Zurück zum Zitat Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11–20.PubMedCrossRef
10.
Zurück zum Zitat Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef Johansen JS, Baslund B, Garbarsch C, et al. YKL-40 in giant cells and macrophages from patients with giant cell arteritis. Arthritis Rheum. 1999;42:2624–30.PubMedCrossRef
11.
Zurück zum Zitat Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.PubMedCrossRef
12.
Zurück zum Zitat Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef Liu X, Zhang Y, Zhu Z, Ha M, Wang Y. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with colorectal cancer. Med Oncol. 2014;31:85.PubMedCrossRef
13.
Zurück zum Zitat Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef Tschirdewahn S, Reis H, Niedworok C, et al. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. Urol Oncol. 2014;32:663–9.PubMedCrossRef
14.
Zurück zum Zitat Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef Schultz NA, Christensen IJ, Werner J, et al. Diagnostic and prognostic impact of circulating YKL-40, IL-6, and CA 19.9 in patients with pancreatic cancer. PLoS One. 2013;8:e67059.PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef Wang D, Zhai B, Hu F, et al. High YKL-40 serum concentration is correlated with prognosis of Chinese patients with breast cancer. PLoS One. 2012;7:e51127.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Itik V, Kemik O, Kemik A, et al. Serum YKL-40 Levels in patients with Gastric cancer. Biomark Cancer. 2011;3:25–30.PubMedCentralPubMed Itik V, Kemik O, Kemik A, et al. Serum YKL-40 Levels in patients with Gastric cancer. Biomark Cancer. 2011;3:25–30.PubMedCentralPubMed
17.
Zurück zum Zitat Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed Fan JT, Li MJ, Shen P, et al. Serum and tissue level of YKL-40 in endometrial cancer. Eur J Gynaecol Oncol. 2014;35:304–8.PubMed
18.
Zurück zum Zitat Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef Peng C, Peng J, Jiang L, et al. YKL-40 protein levels and clinical outcome of human endometrial cancer. J Int Med Res. 2010;38:1448–57.PubMedCrossRef
19.
Zurück zum Zitat Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef Thom I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40: an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer. 2010;116:4114–21.PubMedCrossRef
20.
Zurück zum Zitat Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef
24.
Zurück zum Zitat Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol. 2007;104:435–42.PubMedCrossRef
25.
Zurück zum Zitat Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef Fan JT, Si XH, Liao Y, Shen P. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer. Arch Gynecol Obstet. 2013;287:111–5.PubMedCrossRef
26.
Zurück zum Zitat Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4. Si XH, Fan J, Liao Y, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrial carcinoma. J Pract Gynecol. 2011;27:121–4.
27.
Zurück zum Zitat Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80. Zhang X, Yang C, Lv J. Expression and significance of serum HE4 and YKL-40 in patients with endometrial cancer. Progress Obstet Gynecol. 2011;20:377–80.
28.
Zurück zum Zitat Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011. Wei P. Expression and clinical significance of YKL-40 in endometrial carcinoma. Peking: Peking Union Medical College; 2011.
29.
Zurück zum Zitat Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011. Geng X. The research of YKL-40 and CA125 in diagnosis of endometrial carcinoma. Guangxi: Guangxi Medical University; 2011.
30.
Zurück zum Zitat Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007. Yu M. The preliminary investigation of YKL-40 in the diagnosis of endometrial carcinoma. Sichuan: Sichuan University; 2007.
31.
Zurück zum Zitat Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef Chung HH, Kim JW, Park NH, et al. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet Gynecol Scand. 2006;85:1501–5.PubMedCrossRef
32.
Zurück zum Zitat Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203(228):e1–6.
33.
Zurück zum Zitat Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol. 2009;20:71–7.PubMedCrossRef
34.
Zurück zum Zitat Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef Chudecka-Glaz AM, Cymbaluk-Ploska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014;7:62.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56:1129–35.PubMedCrossRef
Metadaten
Titel
Diagnostic role of circulating YKL-40 in endometrial carcinoma patients: a meta-analysis of seven related studies
verfasst von
Daye Cheng
Ying Sun
Hu He
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 12/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0326-8

Weitere Artikel der Ausgabe 12/2014

Medical Oncology 12/2014 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.